Although cell surface markers expressed on CML LSCs and normal HSCs are mostly similar, the expression levels of some markers are much greater in LSCs than in HSCs, providing an opportunity for molecules targeting cell surface receptors of CML LSCs using antibodies. This evidence concerns the gene CD177 and chronic myelogenous leukemia, BCR-ABL1 positive.